Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press5910.17650/1726-9776-2010-6-2-63-68CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙA CASE OF COMPLETE RECOVERY OF DISSEMINATED RENAL ALLOGRAFT TUMORВОЗМОЖНОСТИ МУЛЬТИМОДАЛЬНОГО ЛЕЧЕНИЯ МЕТАСТАТИЧЕСКОЙ ФОРМЫ РАБДОМИОСАРКОМЫ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫKaryakinO. B.КарякинО. Б.
Russian Federation
karyakin@mrrc.obninsk.ruBashkatovS. V.БашкатовС. В.
Russian Federation
karyakin@mrrc.obninsk.ruTerekhovO. V.ТереховО. В.
Russian Federation
karyakin@mrrc.obninsk.ruNeledovD. V.НеледовД. В.
Russian Federation
karyakin@mrrc.obninsk.ruGorbanN. A.ГорбаньН. А.
Russian Federation
karyakin@mrrc.obninsk.ruGumenetskayaYu. V.ГуменецкаяЮ. В.
Russian Federation
karyakin@mrrc.obninsk.ruDonichkinaE. A.ДоничкинаЕ. А.
Russian Federation
karyakin@mrrc.obninsk.ruMedical radiology research center, Russian academy of medical sciences, ObninskМРНЦ РАМН, Обнинск300620106263682507201425072014https://oncourology.abvpress.ru/oncur/article/view/59

Rhabdomyosarcoma is the most common soft tissue tumor in children aged less than 19 years. In the represented case report, polychemotherapy at Stage 1 of treatment resulted in a complete regression of metastases in the lung and pleura, normalization of the patients health status within 18 months. Consolidation radiotherapy directed to the prostate and femoral bones could achieve a local control over these foci. The emerged recurrence was located in the lung and pleura. The effect of second-line chemotherapy did not exceed 3 months. Despite primary disease dissemination and poor prognosis, disease stabilization and better quality of life (improved general condition, recovery of spontaneous urination, relief and complete disappearance of pain) could be achieved at therapy month 27.

Рабдомиосаркома - наиболее часто встречающаяся опухоль мягких тканей у детей в возрасте до 19 лет. В представленном клиническом случае проведение полихимиотерапии на I этапе лечения привело к полной регрессии метастазов в легких и плевре, нормализации состояния больного в течение 18 мес. Проведение консолидирующей лучевой терапии на предстательную железу и бедренные кости позволило добиться локального контроля над этими очагами. Возникший рецидив заболевания локализовался в легких и плевре. Длительность эффекта 2-й линии химиотерапии не превышала 3 мес. Несмотря на первичную диссеминацию заболевания и неблагоприятный прогноз, удалось на 27-м месяце терапии добиться стабилизации болезни и повышения качества жизни - улучшения общего состояния больного, восстановления самостоятельного мочеиспускания, уменьшения, полного исчезновения болей.

prostate rhabdosarcomametastatic spreadmultimodal treatmentрабдосаркома предстательной железыметастазированиемультимодальное лечение1. Gurney J.G., Young J.L., Roffers S.D. et al. Soft tissue sarcomas. In: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Ries L.A.G., Smith M.A.,Gurney J.G. et al. eds. SEER Program, NIH Pub. 99-4649. Bethesda, MD, National Cancer Institute, 1999.Gurney J.G., Young J.L., Roffers S.D. et al. Soft tissue sarcomas. In: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Ries L.A.G., Smith M.A.,Gurney J.G. et al. eds. SEER Program, NIH Pub. 99-4649. Bethesda, MD, National Cancer Institute, 1999.2. Maurer H.M., Gehan E.A., Beltangady M. et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.Maurer H.M., Gehan E.A., Beltangady M. et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.3. Maurer H.M., Beltangady M.,Gehan E.A. et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.Maurer H.M., Beltangady M.,Gehan E.A. et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20.4. Crist W., Gehan E.A., Ragab A.H. et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30.Crist W., Gehan E.A., Ragab A.H. et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30.5. Green D.M., Jaffe N. Progress and controversy in the treatment of childhood rhabdomyosarcoma. Cancer Treatment Rev 1978;5(1):7-27.Green D.M., Jaffe N. Progress and controversy in the treatment of childhood rhabdomyosarcoma. Cancer Treatment Rev 1978;5(1):7-27.6. Wiltshaw E., Gowing N.F., Stuart-Harris R. et al. Chemotherapy of endodermal sinus tumour (yolk sac tumour) of the ovary: preliminary communication. J R Soc Med 1982;75(11)888-92.Wiltshaw E., Gowing N.F., Stuart-Harris R. et al. Chemotherapy of endodermal sinus tumour (yolk sac tumour) of the ovary: preliminary communication. J R Soc Med 1982;75(11)888-92.7. Bode U. Methotrexate as relapse therapy for rhabdomyosarcoma. Am J Pediatr Hematol Oncol 1986;8(1):70-2.Bode U. Methotrexate as relapse therapy for rhabdomyosarcoma. Am J Pediatr Hematol Oncol 1986;8(1):70-2.8. Horowitz M.E., Etcubanas E.,Christensen M.L. et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol1988;6(2):308-14.Horowitz M.E., Etcubanas E.,Christensen M.L. et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol1988;6(2):308-14.9. Otten J., Flamant F., Rodary C. et al. Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy (a SIOP study). Cancer Chemoter Pharmacol 1989;24 Suppl:30.Otten J., Flamant F., Rodary C. et al. Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy (a SIOP study). Cancer Chemoter Pharmacol 1989;24 Suppl:30.